IDIX Reports Initial Triple Combo Data On IDX184

Analyst Brian Skorney of ThinkEquity Partners maintains his "hold" rating on Idenix Pharmaceuticals (NASDAQ: IDIX).

The key driver of Idenix Pharmaceuticals’ shares is the company's proprietary nucleotide analog polymerase inhibitor, IDX184. IDIX has reported top-line results from the ongoing 14-day triple combo study of IDX184. The results are “a good step toward demonstrating the viability of IDX184 as a STAT-C therapy, and we view nucleos(t)ide polymerase inhibitors (nukes) as potential backbones of treatment,” the analyst says.

ThinkEquity Partners adds, however, that “we temper our enthusiasm for IDX184 with caution given the history of the class to date and what we perceive as a more complicated molecule to develop than protease inhibitors and non-nucleoside polymerase inhibitors.”

More Analyst Ratings here